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Background: The incidence of the inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease
(CD), has been increasing in Asia. We probed the nationwide registered database to assess the incidence,
prevalence, gender distribution, age of diagnosis and the survival status of IBD patients in Taiwan.
Methods: A retrospective study was conducted to analyze the registered database compiled by the National
Health Insurance provided by the Department of Health, Taiwan, from January 1998 through December 2008.
Results: A total of 1591 IBD patients were registered from 1998 to 2008 in Taiwan (CD: 385; UC: 1206). The
incidence of CD increased from 0.19/100,000 in 1998 to 0.24/100,000 in 2008. The incidence of UC increased from
0.61/100,000 in 1998 to 0.94/100,000 in 2008. The prevalence of CD increased from 0.19/100,000 in 1998 to 1.78/
100,000 in 2008. The prevalence of UC increased from 0.61/100,000 in 1998 to 7.62/100,000 in 2008. Male to female
ratio for CD was 2.22 and 1.64 for UC. Age of registered for CD was predominantly between 20 to 39, and for UC
between 30 to 49 years of age. The standardized mortality ratio (95% CI) was 4.97 (3.72–6.63) for CD and 1.78 (1.46–2.17)
for UC, from 1998 to 2008 in Taiwan.
Conclusions: Using the Taiwan nationwide database for IBD, the incidence and prevalence of IBD in Taiwan significantly
increased from 1998 to 2008. The mortality rate was higher for CD patients than UC patients, and both were higher than
the general population.
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The inflammatory bowel diseases (IBDs) Crohn’s disease
(CD) and ulcerative colitis (UC) are common causes of
chronic gastrointestinal disease in the developed world.
Initially regarded as a Western lifestyle disease, inflamma-
tory bowel disease (IBD) is increasing in both incidence
and prevalence in many parts of the Asia Pacific area
[1-8]. The reason for this increasing trend has not been
established but is most likely related to environment fac-
tors, including improved hygiene and “Westernization” of
diet [9].* Correspondence: jmwong@ntu.edu.tw; pchen@ntu.edu.tw
1Department of Internal Medicine, National Taiwan University Hospital and
College of Medicine, 7 Chung Shan South Road, Taipei, Taiwan
7Institute of Occupational Medicine and Industrial Hygiene, National Taiwan
University College of Public Health, 17 XuZhou Road, Taipei, Taiwan
© 2013 Wei et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orBased on a hospital (National Taiwan University Hos-
pital)-based analysis, we previously showed that CD as
well as UC has increased in both incidence and preva-
lence in Taiwan [10-12]. The National Taiwan University
Hospital is a tertiary referral center in Taiwan; with the
first case of ulcerative colitis being diagnosed in 1969.
The previous reports offered a detailed disease pheno-
typic analysis with a long follow-up period (from 1989
to 2008). However, the exact condition of the general in-
cidence and prevalence of CD and UC in Taiwan still
needs a nationwide-based collection of data for a more
representative and comprehensive analysis.
In Taiwan, the National Health Insurance provided by
the Department of Health, Executive Yuan of Taiwan
government was launched in 1995. Almost 99% of the
residents of Taiwan subscribe to this program for their. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Incidence of IBD from 1998–2008 in Taiwan.
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potential for repetitive admissions and the need for
chronic, careful caring, are registered as catastrophic ill-
nesses. When a patient’s ailment is diagnosed by a phys-
ician as a “catastrophic illness” under Department of
Health guidelines, the patient can submit related infor-
mation and apply for a catastrophic illness certificate/
registration. For IBD, the application includes the clin-
ical diagnosis, pathological report as well as the possible
image studies to be formally reviewed to validate and
register the patient’s diagnosis of CD or UC, as well as
for excluding intestinal tuberculosis. In this study, we
used this nationwide-based data set to reveal the inci-
dence, prevalence, age/gender distribution and the mor-
tality rate of IBD patients in Taiwan.
Methods
Data source and ethical considerations
The nationwide population-based Taiwanese study of
IBD was compiled between January 1998 and December
2008. Data was obtained from the Taiwan National
Health Insurance (NHI) research database, which has
been routinely collected by the National Health Research
Institute (NHRI). These high quality databases have pre-
viously been used for epidemiologic research, informa-
tion on prescription use, diagnoses, and hospitalizations
[13-15]. With strict confidentiality guidelines being
closely followed in accordance with personal electronic
data protection regulations; the NHRI anonymized and
maintained the NHI reimbursement data as files suitable
for research. In addition, this study was approved by the
Ethics Review Board at the National Taiwan University
Hospital.
Patient identification
We used the diagnostic code (The International Classifi-
cation of Diseases, Ninth Revision, Clinical Modification
2001 edition) to retrieve the IBD patients (UC: 556.XX;
CD: 555.XX) from the catastrophic illness registration
database. For each patient, medical records were collected
in the NHI claim database, including date of admission,
date of discharge, dates of visits, clinical diagnosis, pre-
scription and total expenditure. The databases also con-
tained patient information, including sex, date of birth
and date of death.
Statistical analyses
The characteristics of IBD patients, including the year of
diagnosis, sex ratio and age distribution, were described
in this study. The annual incidence and prevalence were
defined as the number of newly diagnosed patients and
the number of patients with IBD per 100,000 persons
per year, respectively, namely, the crude incidence and
prevalence. We used the Kaplan-Meier method toestimate IBD cumulative survival rate over an eleven
year follow-up period. To compare with the general popu-
lation of Taiwan, the standardized mortality ratio and 95%
confidence interval were calculated based on the Poisson
assumption. Furthermore, the direct mortality rate was
also standardized to the WHO 2000 standard population
using 5-year age groups per 1,000 person-years. All statis-
tical analyses were performed with the SAS version 9.3
(SAS Institute, Cary, NC, USA). A P value of less than
0.05 was set to declare statistical significance.
Results
A total of 1,591 IBD patients were registered from 1998
to 2008 in Taiwan. Among them, 385 were diagnosed
with CD and 1,206 with UC. As shown in Figure 1, the
incidence of CD increased from 0.19/100,000 in 1998 to
0.24/100,000 in 2008. The incidence of UC increased
from 0.61/100,000 in 1998 to 0.94/100,000 in 2008.
When this period was arbitrarily divided into the first
stage as 1998 to 2003 and second stage from 2004 to
2008, the mean incidence for CD in the first stage was
0.16/100,000 and 0.22/100,000 for the second stage; the
incidence of CD increased significantly from the first
stage to the second stage (p = 0.005). For UC, the mean
incidence in the first stage was 0.70/100,000 and 0.88/
100,000 for the second stage; the incidence of UC in-
creased also significantly from the first stage to the sec-
ond stage (p = 0.047).
As shown in Figure 2, the prevalence of CD increased
from 0.19/100,000 in 1998 to 1.78/100,000 in 2008. The
prevalence of UC increased from 0.62/100,000 in 1998
to 7.62/100,000 in 2008. The mean prevalence for CD in
the first stage was 0.51/100,000 and 1.42/100,000 for the
second stage; the prevalence of CD increased significantly
from the first stage to the second stage (p = 0.0003). For
UC, the mean prevalence in the first stage was 2.2/
100,000 and 6.12/100,000 for the second stage; the preva-
lence of UC increased also significantly from the first stage
to the second stage (p = 0.0005).
The year of diagnosis and sex-specific number of pa-
tients with CD and UC in Taiwan from 1998 to 2008 are
Figure 2 Prevalence of IBD from 1998–2008 in Taiwan.
Table 2 Sex- and age-specific number of patients registered
as Crohn’s disease in Taiwan, 1998-2008
Age group Male Female Total
0–9 18 8 26
10–19 30 16 46
20–29 77 17 94
30–39 72 30 102
40–49 56 26 82
50–59 26 23 49
60–69 22 14 36
70–79 18 7 25
≥80 1 5 6
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patients registered with CD are summarized in Table 2,
and for UC in Table 3. The age of registration for CD
patients was primarily between 20 to 39 (Figure 3), with
the mean and standard deviation of 37.8 and 18.8 years
of age, respectively. The age of registration for UC was
mostly between 30 to 49 years old (Figure 4), with the
mean and standard deviation of 44.5 and 15.8 years old,Table 1 Year of diagnosis and sex-specific number of
patients with Crohn’s disease and ulcerative colitis in
Taiwan, 1998-2008
Year of diagnosis Male Female Total Male to female ratio
Crohn’s disease
1998 25 13 38 1.9
1999 18 10 28 1.8
2000 22 10 32 2.2
2001 28 12 40 2.3
2002 27 9 36 3
2003 26 17 43 1.5
2004 37 15 52 2.5
2005 33 15 48 2.2
2006 32 16 48 2
2007 31 14 45 2.2
2008 41 15 56 2.7
Ulcerative colitis
1998 69 49 118 1.4
1999 91 44 135 2.1
2000 78 42 120 1.9
2001 82 37 119 2.2
2002 113 76 189 1.5
2003 123 72 195 1.7
2004 100 69 169 1.4
2005 136 85 221 1.6
2006 116 85 201 1.4
2007 119 74 193 1.6
2008 123 95 218 1.3respectively. Male to female ratios for CD was 2.22 and
1.64 for UC. These ratios reflect a male predominant
pattern in Taiwan for CD over UC (p = 0.01) (Figure 5).
As shown in Figure 6, the survival status of CD pa-
tients after registration for one year, 5 years and 10 years
were: 96%, 90% and 82%, respectively. For UC patients,
the survival status after registration for one year, 5 years
and 10 years were: 99%, 95% and 90%, respectively.
There was a statistical difference between the survival
status of UC and CD patients from 1998 to 2008 in
Taiwan (p = 0.001). The standardized mortality ratio
(95% CI) was 4.97 (3.72–6.63) and the standardized mor-
tality rate (per 1,000 person-years) was 29.7 for CD; and
the standardized mortality ratio (95% CI) was 1.78
(1.46–2.17) with the standardized mortality rate (per
1,000 person-years) of 9.62 for UC from 1998 to 2008 in
Taiwan.
Discussion
Increased incidence and prevalence of IBD in Asia have
been reported [1,3-12]. This information is mostly based
on hospital-based data except for a report from Japan
where there is a nationwide registration system [16].
By using a nationwide registration system in Taiwan,Table 3 Sex- and age-specific number of patients registered
as ulcerative colitis in Taiwan, 1998-2008
Age group Male Female Total
0–9 8 3 11
10–19 34 26 60
20–29 175 76 251
30–39 290 164 454
40–49 264 162 426
50–59 193 138 331
60–69 109 92 201
70–79 61 58 119
≥80 16 9 25
Figure 3 Age and sex distribution of Crohn’s disease patients
from 1998–2008 in Taiwan.
Figure 5 Gender ratio (male to female) of IBD patients in
Taiwan from 1998 to 2008.
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nationwide-based data analysis in Asia, which con-
firmed that the incidence and prevalence of IBD in-
creased from 1998 to 2008 in Taiwan. From our
experience, the true IBD patient number should be more
than the registered number as there are always IBD pa-
tients who have not yet registered or who have not passed
the registration process, therefore, there is no way to know
the real number. The bottom line is that we have at least
the number of cases reported in this study with a con-
firmed diagnosis of IBD and the number of cases in-
creased significantly over the past years in Taiwan.
Although the incidence (CD: 0.24/100,000; UC: 0.94/
100,000, in 2008) and prevalence (CD: 1.78/100,000; UC:
7.62/100,000, in 2008) increased in Taiwan, they were still
lower than the reports from Japan (prevalence: approxi-
mately 21/100,000 for CD and 63.6/100,000 for UC),
Korea (prevalence: approximately 11/100,000 for CD andFigure 4 Age and sex distribution of ulcerative colitis patients
from 1998–2008 in Taiwan.30.9/100,000 for UC), and much lower than those from
Western Countries (prevalence: approximately 200/
100,000 for CD and 400/100,000 for UC) [1,9,16]. And
according to the recently pusblised large scale population-
based epidemiologic study across nine countries in Asia-
Pacific showing geographic variability in disease incidence
even within Asia [17]. Taiwan appeared to have disease in-
cidence that is lower than Hong Kong, some parts of
mainland China, and Macau, and relatively similar to that
of Malaysia and Sri Lanka, but higher than those of
Thailand and Indonesia. One may speculate that different
degrees of urbanization/socioeconomic status may play a
part in the variation.
The mean age of patients registered with CD was 37.8
and for UC was 44.5 years of age. We previously have
shown that, based on a referral center in Taiwan, the
mean age of diagnosis for CD was 30.5 and for UC was
36 in the National Taiwan University Hospital [11,12].
This difference might be related to the lag between diag-
nosis and registration, as well as the possible gap between
the IBD diagnosis efficiency between an experienced cen-
ter and the other general hospitals. Nonetheless, the mean
age for CD and UC registered patients was still within the
range reported from other countries in Asia [16].
Considering the male to female ratio, in the current
study we found the ratio for CD was 2.22 and for UC was
1.64, which was consistent with our previous results which
showed 1.82 for CD and 1.35 for UC [11,12]. Both diseases
showed a male predominant pattern, especially significant
for CD. This observation was consistent with the reports
from the other Asian countries, most of them revealed a
male predominant prevalence. Interestingly, this differed
from reports from Western countries [16,18].
The survival status, or vice versa, the mortality rate
from this report was quite different from previous re-
ports, even when compared to our previous results
based on a referral center follow-up study which showed
the accumulated mortality rate for CD to be 2.7% (3 of
110) and 1.72% for UC (7 of 406) from 1988 to 2008. In
Figure 6 Survival rate of IBD patients in Taiwan from 1998 to 2008.
Wei et al. BMC Gastroenterology 2013, 13:166 Page 5 of 6
http://www.biomedcentral.com/1471-230X/13/166this study, the survival rate of CD patients after the
registration for one year, 5 years and 10 years were: 96%,
90% and 82%, respectively. For UC patients, the survival
status after the registration for one year, 5 years and
10 years were: 99%, 95% and 90%, respectively. There
was a statistical difference of the survival status between
UC and CD patients from 1998 to 2008 in Taiwan (p =
0.001). When compared with the general population, the
standardized mortality ratio (95% CI) was 4.97 (3.72–
6.63) and the standardized mortality rate (per 1,000
person-years) was 29.7 for CD; the standardized mortal-
ity ratio (95% CI) was 1.78 (1.46–2.17) with the stan-
dardized mortality rate (per 1,000 person-years) as 9.62
for UC from 1998 to 2008 in Taiwan. Both were higher
than the reports from Japan as well as from most West-
ern countries, with the standardized mortality ratio for
CD around 1.5 fold the general population. The mortal-
ity rate of CD patients was slightly higher than the gen-
eral population and the mortality rates for UC patients,
either from Japan or from Western countries were
mostly the same as the general population [19-31].
The higher mortality shown in this study was unex-
pected. However, as the data was anonymized, only the
date of death but not the cause of death nor comorbidity
could be traced from this data set. The registered data
only provided the diagnosis, no phenotypic information
was included. Therefore, we were not able to know
whether the higher mortality resulted from the severity
of the disease or not. The ages of diagnosis in this co-
hort were comparable to the reports from other Asian
countries [1,17,30], age did not seem to be able to ex-
plain the higher mortality. However, when comparing
the results from a referral center (National Taiwan
University Hospital, for example) with the nationwide
population-base, patients tended to be diagnosed at
earlier ages and with less mortality when seen in a re-
ferral center. This result might reflect the low awarenessof IBD in the general practice, since previously in Taiwan,
IBD was a relatively low prevalence disease. Experience
diagnosing and treating IBD patients when they presented
outside the referral center (NTUH, for example) was lag-
ging. Therefore, since 2010, we have started to emphasize
the increasing trend of IBD as well as an IBD awareness
education program. Hopefully in the future, we can im-
prove the awareness, the quality of care, and the outcome
of IBD patients in Taiwan. Our experience might also af-
ford other countries where IBD is low in prevalence, to
modify their quality of care in treating IBD patients which
should translate into improving the prognosis of IBD
patients.
Conclusion
Using the Taiwan nationwide database for IBD, the inci-
dence and prevalence of IBD in Taiwan significantly in-
creased from 1998 to 2008.
The mortality rate was higher for CD patients than
UC patients, and both were higher than the general
population. After our promotion of the disease aware-
ness, we hope the outcome of IBD patients in Taiwan
could be improved in the future.
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